Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yep, lost a bit here from ‘18 until I was able to get out nearly even in the ‘20 mania where even $hit like this got pumped. Definitely buyer beware. Don’t be stupid like I was…no bid will return here.
Back in here @ .319, looks primed for a run up into earnings
Nice support, looks to have further upside next week
I spoke too soon...0.38 to 0.28 in three days? Yikes. Yearly triple bottom, let’s see if it bounces from here
.35 and .36 broke and held today! Nice green day within a sea of red. Seems like more action to be expected for this ticker in the next few weeks
Was just loading in AH too. In for a short term bounce off support here. Ready to increase position size on low volume break of support
This is a quote I saw from another member on this board in which he interpreted the deal with Biolidics to be “soured”:
“How hard would it be for the CEO to state exactly what you have claimed he said considering the soured deal with Biolitics?”
While I don’t agree with this label, I do understand it because a distribution deal was terminated. However, a new LOI has come out of this to jointly develop and market a next-gen diagnostic test for SARS-CoV-2, so dealings with Biolidics aren’t truly “soured” all things considered.
My point is you really have to give Aytu and Biolidics credit for their mutual agreement to terminate a rapid test that simply couldn’t compete with similar tests from market-leading players and for their adaptation to the evolving COVID-19 situation, which is currently calling for a test that can be administered easily at home and delivers rapid, accurate results. Glty
Great points. However, I think the market’s uncertainty is temporary. When the market digests that the majority of kits still in storage are Orient Gene’s rapid IgG/IgM tests (still one of the best on the market in terms of speed of reporting test results and minimization of false positive/false negative rates), and that specific agreement is still very much in place, I think this fear mongering about Aytu no longer being an efficient test kit distributor will be no more. Biolidics’ decision to retire a subpar test and attempt to develop a next-gen test will be lauded. Aytu’s management is attempting to deliver an evolved idea of what rapid testing can mean in the US. From a purely pragmatic standpoint, this move means Biolidics keeps Aytu as future partner distributor assuming the successful creation (may already be advanced patented technology, we don’t know) and passage of regulatory hurdles as you pointed out. The speed with which test results have been delivered to individuals in need in the US has been thoroughly disappointing given the current state of next-gen molecular DNA diagnostic technologies. I work directly with these technologies on the daily and my lab is developing a new “next-gen” technology, so I see the disconnect between what our healthcare system is able to provide and what is possible.
If the main concern is dilution to shareholders—which I’ve also heard—the same filing also states HC Wainwright gets only ~900k warrants at 1.76 with fees. Where is the dilution? Only an outstanding ATM but they aren’t going to raise additional capital in the paltry $1-$2 range (I’d think). Glty Drugdoc
For those here who don’t read filings, and I know you exist. This site has more informed traders/investors than Stocktwits, that’s for sure:
“On June 27, 2020, Aytu BioScience, Inc. (the “Company”) and Biolidics, Limited (“Biolidics”) signed a letter of intent to, among other things, document the parties’ mutual intention to enter into a joint development agreement (the “Joint Development Agreement”) in order to advance the development of and, if successful, commercialize a new SARS-CoV-2 diagnostic test (the "Proposed Collaboration"). The Company and Biolidics are in the process of negotiating the definitive terms of this Proposed Collaboration. The Company and Biolidics believe a next generation SARS-CoV-2 test may address an important clinical need as the 2019 Novel Coronavirus (“SARS-CoV-2 coronavirus” or “COVID-19”) health crisis continues to unfold and the needs associated with patient testing continue to evolve. Stockholders are reminded that there can be no assurance the Company will enter into a Joint Development Agreement with Biolidics for the Proposed Collaboration or that a new SARS-CoV-2 diagnostic test will be successfully developed. The Company will make the appropriate announcement(s) if and when there are further material developments relating to the Proposed Collaboration.”
I don’t know how anyone can construe this as anything other than rapid adaptation to meet new demand as the pandemic unfolds, let alone a botched deal.
Scooped some .072s yesterday, we’ll see how they fare here. TOMDF should see FDA EUA within the next week I’d imagine
Right on doog hope you’ve been doing well. Eyeing the 0.265 support line, let’s see if it holds
Two shares of IMPACT IPO for every one share DSS owned (i.e. if you own 10k DSS shares, you would apparently be entitled to a bonus of 20k IMPACT shares post IPO).
“The Term Sheet further lay out the intention to give a dividend of IMPACT shares to the shareholders (excluding the controlling shareholders of DSS and the chairman’s group of companies). The proposed bonus being, for every one DSS share held, the shareholder will be entitled to a bonus of two IMPACT shares. Following that, IMPACT is to pursue an initial public offering.”
Had to flip shares at 0.33, looking for reentry!
In for starter here, now with expanded distribution agreements. A long list of expansions at that!
44s going already premarket...let’s see if news drops
Up 46% now on TASE! Thanks for the heads up.
38s going in AH
33% institutional ownership and 8% insider ownership as well. FWIW
From yearly report:
Cash & Cash Equivalents
At December 31, 2019, the Company had $4.4 million in cash and cash equivalents compared to $5.2 million at the end of December 2018. In January 2020, Kitov received a $1.5 million milestone payment from Coeptis. This payment, in addition to the $3.5 million financing from Pontifax, Orbimed and Arkin, equates to a proforma cash position of approximately $9.5 million at December 31, 2019.
Combined with the $6.0 mil cash from offering less any expenses since the report, cash on hand would be between $9.5 and $15.5 mil. You’re telling me this company is potentially valued at 0.75-1.1x the cash & cash equivalents? And launch of FDA approved combination athritis/hypertension treatment this upcoming quarter with at least $10 mil revs expected per year from this new treatment thereafter?
Increased my position size...
Loaded more @ 0.305. Incredible news
KTOV in @ 0.278. Technical and fundamental bounce underway with possible news incoming
CEO mentioned on CC that R/S wasn’t needed as NASDAQ will grant extension for many companies in light of recent market conditions. There are companies worse than this one that are receiving 180 day extensions. Good luck.
Nice revenue growth!
BIOC currently has book value of $0.66, price to book ratio of 0.53. No offerings for the rest of 2020 and filed for Nasdaq extension. Undervalued.
Lmao it would be sweet to turn over a new leaf with BIOC, right Sweetleaf? Just watch
No doubt! I think this route for them makes perfect sense but we shall see
From PR on 8/13/19:
"Collectively, the granting of these additional patents further broadens Biocept's U.S. and international footprint for capturing and analyzing any biological target of interest," said Lyle Arnold, Ph.D., Chief Scientific Officer at Biocept. "For Biocept's core business, this includes CTCs from any sample type, however these patents also expand the use of Biocept's technologies well beyond its current core business and may provide opportunities to out-license our technologies for a variety of uses."
I think it’s more likely they announce a large licensing deal for their Target Selector liquid biopsy for COVID-19, so as to adhere to their core business model while still capitalizing on the versatility of their tech
Their Target Selector test can easily be modified for any serological targets, so yes in principle. Offering their platform for these purposes would be capitalizing on the current situation and I believe it’s likely they have done so and revs will reflect this.
One more thing is consistent revenue growth shows their diagnostic technology is gaining traction in many clinics/hospitals across the country. It’s a mid-long term hold for me, although I think many are here short term because of expectations for a blowout 4th quarter and annual report.
Thanks for the reply. You’re right in that their at-the-market offerings caused the decline in SP. Although this option was much better for shareholders than issuing warrants or taking on convertible debt.
This company has novel liquid biopsy tests for various cancers. Liquid biopsy tech was just discussed in a cancer class I took just under a year ago as the forefront of innovation in that these tests are more accurate, less invasive, and more adaptable to a broad array of target cancers than are traditional biopsies.
Sometimes, as with lung cancer, taking a solid biopsy is impractical, and in these cases noninvasive liquid biopsy will gain market share in the long run. So yes, I think this company can stand alone even if no COVID-19 licensing deal comes to fruition. No hype, just speculation that external labs could easily use their test with modified qPCR primers to test for COVID-19 in principle. Glty
Hope there is some mention/reminder of at least this licensing possibility in today’s company update if licensing deals that were for some reason never PR’d are not already reflected in revs!
From PR on 8/13/19:
"Collectively, the granting of these additional patents further broadens Biocept's U.S. and international footprint for capturing and analyzing any biological target of interest," said Lyle Arnold, Ph.D., Chief Scientific Officer at Biocept. "For Biocept's core business, this includes CTCs from any sample type, however these patents also expand the use of Biocept's technologies well beyond its current core business and may provide opportunities to out-license our technologies for a variety of uses."
Make of this what you will. I strongly believe a large licensing deal will be announced for their Target Selector liquid biopsy for COVID-19. It makes perfect sense. Rapid blood/plasma-based tests have been coming to market of late, and qPCR is the diagnostic method used in the earlier swab-based tests for viral nucleic acid. If they change the desired target to a viral surface marker by redesigning qPCR primers, it could be done. I hope they capitalize on this.
BIOC looks ready. In at 0.31. Under offering prices 0.4-0.41? No brainer imo
https://www.pharmatechsolutions.co/assets/inserts/20200313_GenViro!_PP.pdf
Here is the link. This tech looks great, nice idea to use monoclonal Ab for a specific viral envelope marker. Read current biophysics/bioelectronics/materials science journals and you’ll see that many biosensor technologies have used a similar design. Concept has been validated in these additional studies.
I agree it would be refreshing to see false positive and false negative rates. But from what I’ve read, there can be a relatively large margin of error and FDA can still deem the test effective. These types of diagnostic tests have less stringent efficacy criteria than molecular amplification-based diagnostics.
Glty
It’s impedance, impedance increases when more viral protein is bound to the antibody fixed to the substrate. Can change which virus is detected by swapping the fixed antibody. Read the PowerPoint presentation!
Hi all, paid up for 3s, don’t expect to be disappointed with this one! Should be LEGENDARY ;)
Picked up a decent starter, looks coiled tight in this range. Despite the fundamentals here with the FDA-designated breakthrough device (Hemopurifier), the pandemic clamor may bring a quick pop eod or Monday/Tuesday. IMO
What about the potential of Ras inhibition in treating many human cancers? It seems like you only care about the daily price movements. In which case, we’re here for very different reasons.
It may hit your target, but long term, this looks like an easy bet. I’m in the AML/MDS field, and while there may be even better options for MDS (theoretically), those treatments are early stage preclinical. Oncogenic Ras inhibition makes perfect sense from a targeting perspective and should help many as a treatment. Way better than currently approved alternatives. I expect favorable topline phase 3 data soon. No way the FDA doesn’t eventually approve. Didn’t mean to offend. Glty
I have a bid in, wasn’t me who scored, but still hoping for a bite. Nice pond fishing play. We’ll see shortly if paying up for 3s will be necessary
HMA treatments are definitely archaic and lacking in efficacy. I work in acute myeloid leukemia treatment research, and so much of the field is still trying to figure out the best therapeutic targets. MDS can progress to AML in many cases so I’ve studied MDS extensively. It’s a no brainer that Onconova will meet their endpoint of higher overall patient survival with rigosertib compared to HMAs, IMO. Ras inhibition should play out nicely for them given results in previous nonhuman models.